Armand Aviges
Partner
Practice areas
Career:
- Bar admission: 2005
- Graduate from the University of Paris I (Panthéon-Sorbonne), Paris II (Pantheon-Assas) and the University of “La Sapienza” (Rome)
- Partner at Armfelt (2011)
- Partner at ADVANT Altana (2016)
Practice Areas:
- Product Liability
- Health Law
- Intellectual property
- Unfair competition
- Unified Patent Court (UPC)
Areas of Expertise:
- advises, assists and represents both French and international industrial players, particularly in the pharmaceutical sector, in product liability matters before various jurisdictions (civil, administrative and criminal). He notably handles complex serial claims and has developed a strong expertise in healthcare class actions and notably represents a leading pharmaceutical group in the first two pharmaceutical class actions in France. His practice has a decidedly international bent, as he manages and coordinates mass disputes on an international level.
- assists pharmaceutical industries in all matters relating to intellectual property law (with particular focus on fields such as patents, trademarks, know-how and employee’s invention) and has developed a significant practice in the field of customs legislation related to falsified / counterfeit medicinal products.
- he is also regularly consulted in the context of reflexions and proposals concerning draft bills or the modification of the French legal system.
Languages:
- French
- English
- Italian
Distinctions:
- Best Lawyers – recognized since 2020 (Biotechnology and Life Sciences Practice | Intellectual Property Law | Litigation | Product Liability Litigation)
- Chambers Europe 2023 – Pharma/Life Sciences: Product Liability – France – Band 2
- Legal 500 EMEA 2023 – Industry focus : Healthcare & life sciences – Tier 1 (Leading Individuals)
- Legal 500 EMEA 2023 – Intellectual Property : Patents – Tier 4
- Option Droit & Affaires 2022 – Contentieux : Contentieux des produits défectueux et des sinistres – 1 étoile
- Décideurs (Leaders League) 2022 – Risques industriels & contentieux de la responsabilité : Responsabilité du fait des produits – Excellent
- Décideurs (Leaders League) 2023 – Propriété Industrielle – Brevets : Contentieux – Forte notoriété
- Décideurs (Leaders League) 2023 – Propriété Industrielle – Gestion de portefeuilles de marques, dessins et modèles – Forte notoriété
- Décideurs (Leaders League) 2023 – Propriété Industrielle – Marques : Contentieux – Forte notoriété
- Décideurs (Leaders League) 2022 – Brevets : contentieux pharma, biotechs et sciences de la vie – Forte notoriété
- Décideurs (Leaders League) 2022 – Santé, Pharma & Biotechnologies : Responsabilité du fait des produits – Incontournable
- Décideurs (Leaders League) 2022 – Santé, Pharma & Biotechnologies : Droit pénal de la santé – Excellent
- Décideurs (Leaders League) 2022 – Santé, Pharma & Biotechnologies : Santé électronique – Forte notoriété
- Décideurs (Leaders League) 2022 – Santé, Pharma & Biotechnologies : Contrats de licensing, Co-développement et R&D – Forte notoriété
Publications:
- “Implant files’: Paris administrative court places cursor between freedom of speech and business secrecy”, Lexology, January 2021
- “Baclofene saga continues”, Lexology, December 2020
- “Suspension of decision granting Baclocur market authorisation when decision is based on compromise rather than scientific knowledge”, Lexology, September 2020
- “COVID-19: French Administrative Supreme Court rulings on interim measures challenging government policies”, Lexology, April 2020
Published news
Altana continues its expansion
23/01/2017
- Awards and nominations
- Articles and publications
Altana, in keeping with its strategy of continuous managed growth, is pleased to announce the reinforcement of its litigation and arbitration practices and expansion into… Read more
Altana continues its expansion
23/01/2017 - Awards and nominations - Articles and publications
Altana, in keeping with its strategy of continuous managed growth, is pleased to announce the reinforcement of its litigation and arbitration practices and expansion into… Read more
Linked news
Retour sur la difficile conciliation entre liberté de la presse et prévention des abus de marché
18/07/2024
- Articles and publications
Liberté fondamentale garantie par la loi du 29 juillet 1881 et l’article 10… Read more
Fil Rouge : CNIL recommendations on the development of AI systems
04/07/2024
- Videos
The CNIL has published practical information sheets to guide professionals in the design… Read more
[Petit déjeuner Conférence] De la conception à l’utilisation des systèmes IA : quels risques et quelles nouvelles obligations ?
17/06/2024
- Events
Sorry, this entry is only available in… Read more
View all news
Retour sur la difficile conciliation entre liberté de la presse et prévention des abus de marché
18/07/2024 - Articles and publications
Liberté fondamentale garantie par la loi du 29 juillet 1881 et l’article 10… Read more
Fil Rouge : CNIL recommendations on the development of AI systems
04/07/2024 - Videos
The CNIL has published practical information sheets to guide professionals in the design… Read more
[Petit déjeuner Conférence] De la conception à l’utilisation des systèmes IA : quels risques et quelles nouvelles obligations ?
17/06/2024 - Events
Sorry, this entry is only available in… Read more
